LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

Home・Aandelen Lijst・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Gesloten

SectorGezondheidszorg

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	-0.05% downside

Mirati Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 mrt 2026, 19:18 UTC

Belangrijke Marktbewegers

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

11 mrt 2026, 23:54 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

11 mrt 2026, 23:54 UTC

Marktinformatie

Nikkei May Decline on Energy Costs Concerns -- Market Talk

11 mrt 2026, 23:51 UTC

Marktinformatie

Gold Falls as Rising Oil Prices Spur Inflation Worries -- Market Talk

11 mrt 2026, 23:41 UTC

Marktinformatie

REA Bull Sees Potential Upside to Yield Guidance -- Market Talk

11 mrt 2026, 23:37 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Rise Amid Ongoing Middle East Conflict -- Market Talk

11 mrt 2026, 23:17 UTC

Belangrijke Nieuwsgebeurtenissen

Front-Month WTI Crude Oil Futures Rise 5.5% to $92.05/bbl

11 mrt 2026, 23:17 UTC

Belangrijke Nieuwsgebeurtenissen

Front-Month Crude Oil Futures Rise Amid Ongoing Middle East Conflict

11 mrt 2026, 22:29 UTC

Marktinformatie

Australia Shares Set to Fall in Early Trade -- Market Talk

11 mrt 2026, 21:47 UTC

Winsten

Liontown Resources: Market Tailwinds Strengthening Outlook

11 mrt 2026, 21:46 UTC

Winsten

Liontown Resources: 4 Mln Ton Per Annum Expansion Study Underway

11 mrt 2026, 21:45 UTC

Winsten

Liontown Resources Says FY26 Guidance Unchanged

11 mrt 2026, 21:45 UTC

Winsten

Liontown Resources 1H Unit Operating Costs A$985/Ton

11 mrt 2026, 21:44 UTC

Winsten

Liontown Resources 1H Underlying Ebitda Loss A$7.7 Million

11 mrt 2026, 21:43 UTC

Winsten

Liontown Resources 1H Revenue A$207.5 Million

11 mrt 2026, 21:43 UTC

Winsten

Liontown Resources 1H Net Loss A$184 Million

11 mrt 2026, 21:12 UTC

Acquisities, Fusies, Overnames

Netflix Rival Strikes Deal With Google in Battle for AI Content -- Barrons.com

11 mrt 2026, 21:10 UTC

Winsten

Vista Gold FY25 Loss $7.5M >VGZ

11 mrt 2026, 21:10 UTC

Winsten

Vista Gold FY25 Loss/Shr 6c >VGZ

11 mrt 2026, 20:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

11 mrt 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

11 mrt 2026, 20:27 UTC

Acquisities, Fusies, Overnames

Papa John's Draws Fresh Takeover Interest -- 2nd Update

11 mrt 2026, 20:26 UTC

Winsten

These Stocks Are Today's Movers: Oracle, UniFirst, Fair Isaac, Nebius, AeroVironment, Campbell's, and More -- Barrons.com

11 mrt 2026, 20:19 UTC

Belangrijke Nieuwsgebeurtenissen

The Strait of Hormuz Could Take Weeks -- Even Months -- to Reopen, Military Experts Say -- Barrons.com

11 mrt 2026, 20:15 UTC

Winsten

This Physical AI Stock Jumped on Earnings. The Robots Are Coming. -- Barrons.com

11 mrt 2026, 20:12 UTC

Belangrijke Nieuwsgebeurtenissen

Stock Market Today: Oil Prices Push Higher Despite IEA Oil Release Headline -- WSJ

11 mrt 2026, 19:31 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Gain Despite IEA's Planned Release of Reserves -- Market Talk

11 mrt 2026, 19:01 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Natural Gas Gains With Middle East Conflict in View -- Market Talk

11 mrt 2026, 18:59 UTC

Acquisities, Fusies, Overnames

Berkshire's Deal for Occidental Chemicals Unit Is a Winner as Chemical Stocks Surge -- Barrons.com

11 mrt 2026, 18:43 UTC

Belangrijke Nieuwsgebeurtenissen

Chubb Named Lead Insurer for U.S. Plan to Protect Oil Tankers in Strait of Hormuz -- Barrons.com

Peer Vergelijking

Prijswijziging

Mirati Therapeutics Inc Prognose

Koersdoel

By TipRanks

-0.05% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 58.67 USD -0.05%

Hoogste 59 USD

Laagste 58 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Mirati Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Mirati Therapeutics Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

EBITDA

Operationele winst

Over Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.